

Making more of prostate biopsies

Poster Session 49

Sunday, 13 March
15:45 - 17:15

Location: Room Madrid (Hall B2, level 0)

Chairs: C. Beisland, Bergen (NO)
C. Surcel, Bucharest (RO)
G. Van Leenders, Rotterdam (NL)

Aims and objectives of this presentation

To address the role of prostatic biopsies in the diagnosis of early prostate cancer, how to make use of their diagnostic and prognostic value in clinical decision making, and how to improve their diagnostic yield.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 608 **Needle disinfectant technique during prostate biopsy is associated with less infection-related hospitalization: Results from a surgical collaborative**
By: [Ghani K.](#)¹, [Auffenberg G.](#)¹, [Brachulis A.](#)¹, [Linsell S.](#)¹, [Gao Y.](#)¹, [Ye Z.](#)¹, [Kraklau D.](#)², [Montie J.](#)¹, [Miller D.](#)¹
Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²Lakeland Health, Dept. of Urology, St Joseph, United States of America
- 609 **Are all pathologic Gleason scores 8 created equal? Implications for the applicability of new prostate cancer grading system**
By: [Gandaglia G.](#)¹, [Fossati N.](#)², [Bianchi M.](#)³, [Freschi M.](#)⁴, [Doglioni C.](#)⁴, [Farina E.](#)², [Gallina A.](#)², [Stabile A.](#)², [Capitanio U.](#)², [Salonia A.](#)², [Montorsi F.](#)², [Briganti A.](#)²
Institutes:¹Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ³Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ⁴IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy
- 610 **Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy**
By: [Qi R.](#), [Moul J.](#)
Institutes:Duke University Medical Center, Dept. of Urologic Surgery and Duke Cancer Institute, Durham, United States of America
- 611 **Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy**
By: [Kweldam C.F.](#)¹, [Kümmerlin I.P.](#)¹, [Nieboer D.](#)², [Verhoef E.I.](#)¹, [Steyerberg E.W.](#)², [Van Der Kwast T.H.](#)³, [Roobol M.J.](#)⁴, [Van Leenders G.J.L.H.](#)¹
Institutes:¹Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, ³University Health Network, Laboratory Medicine Program, Toronto, Canada, ⁴Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands
- 613 **An improved clinical risk stratification system to better predict cancer specific mortality at diagnosis in primary non-metastatic prostate cancer**
By: [Gnanapragasam V.](#)¹, [Lophatananon A.](#)², [Muir K.](#)³, [Gavin A.](#)⁴, [Wright K.](#)⁵, [Greenberg D.](#)⁵
Institutes:¹University of Cambridge, Dept. of Academic Urology, Cambridge, United Kingdom, ²University of Warwick, Dept. of Health Science, Warwick, United Kingdom, ³University of Manchester, Dept. of Public Health, Manchester, United Kingdom, ⁴Queen's University Belfast, Northern Ireland Cancer Registry, Belfast, United Kingdom, ⁵Public Health England, Cambridge, United Kingdom

- 614 **Morphological and molecular pathway-based analysis of Gleason score 7 prostate cancer using a 17-gene expression assay**
 By: Bonham M.¹, McCullough D.², Lu R.², Bennet J.³, Febbo P.⁴, Tsiatis A.⁵
 Institutes:¹Genomic Health, Dept of Pathology, Redwood City, United States of America, ²Genomic Health, Dept. of Biostatistics, Redwood City, United States of America, ³Genomic Health, Dept. of Data Management, Redwood City, United States of America, ⁴Genomic Health, Dept. of Translational Sciences, Redwood City, United States of America, ⁵Genomic Health, Dept. of Pathology, Redwood City, United States of America
- 615 **Pathological outcomes after radical prostatectomy in men eligible for active surveillance, multi-institutional study**
 By: Mizuno K.¹, Inoue T.², Kinoshita H.³, Yano T.⁴, Kawanishi H.⁵, Kanda H.⁶, Terada N.², Kamba T.², Okumura K.⁵, Kawakita M.⁴, Ogura K.¹, Sugimura Y.⁶, Matsuda T.³, Ogawa O.²
 Institutes:¹Japanese Red Cross Otsu Hospital, Dept. of Urology, Otsu, Japan, ²Kyoto University Graduate School of Medicine, Dept. of Urology, Kyoto, Japan, ³Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan, ⁴Kobe Medical Center General Hospital, Dept. of Urology, Kobe, Japan, ⁵Tenri Hospital, Dept. of Urology, Tenri, Japan, ⁶Mie University Graduate School of Medicine, Dept. of Nephro-Urologic Surgery and Andrology, Tsu, Japan
- 616 **Routine use of magnetic resonance imaging in prostate cancer facilitates better candidate selection for active surveillance**
 By: Sivaraman A., Ahallal Y., Sanchez-Salas R., Barret E., Linares Ospinos E., Perez Regetti J., Russo A., Armando Hernandez Palacios G., Galiano M., Rozet F., Cathelineau X.
 Institutes:Institute Mutualiste Montsouris, Dept. of Urology, Paris, France
- 617 **The value of PSA density in combination with PI-RADS scoring for prostate cancer prediction**
 By: Distler F.¹, Radtke J.P.¹, Bonekamp D.², Roethke M.², Schlemmer H-P.², Roth W.³, Hohenfellner M.¹, Hadaschik B.A.¹
 Institutes:¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ²German Cancer Research Center, Heidelberg, Dept. of Radiology, Heidelberg, Germany, ³University Hospital Heidelberg, Dept. of Pathology, Heidelberg, Germany
- 618 **Impact of targeted prostate biopsy using magnetic resonance imaging – ultrasound elastic fusion in men with suspicion of prostate cancer**
 By: Fourcade A.¹, Perrouin-Verbe M-A.¹, Tissot V.², Serey-Effeil S.¹, Callerot P.¹, Cuvelier G.³, Coquet J-B.⁴, Doucet L.⁵, Delage F.⁴, Deruelle C.⁴, Joulin V.⁴, Fournier G.⁴, Valéri A.⁴
 Institutes:¹University Hospital Of Brest, Department of Urology, Brest, France, ²University Hospital Of Brest, Department of Radiology, Brest, France, ³Hospital of Quimper, Department of Urology, Brest, France, ⁴University Hospital of Brest, Department of Urology, Brest, France, ⁵University Hospital of Brest, Department of Anatomic-Pathology, Brest, France
- 619 **A non-inferiority multicentric controlled trial comparing three MRI-TRUS targeted biopsies to systematic TRUS biopsies for the detection of prostate cancer in patients with a single suspicious focus on prostate MRI: Results of the MURIELLE study**
 By: Delongchamps N.B.¹, Portalez D.², Bruguière E.³, Escourrou C.¹, Casanova J.M.⁴, Roumiguié M.⁵, Hohn N.⁶, Bratan F.⁷, Sanzalone T.⁷, Rouvière O.⁷, Fiard G.⁶, Thoulouzan M.⁵, Malavaud B.⁵, Bordier B.³, Guillotreau J.³, Bouazza N.¹, De Gorski A.⁸, Mozer P.⁸, Aziza R.⁹, Renard-Penna R.⁸, Misrai V.³, Descotes J.L.⁶, Cornud F.¹
 Institutes:¹Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, ²Rangueil University Hospital, Dept. of Radiology, Toulouse, France, ³Clinique Pasteur, Dept. of Urology, Toulouse, France, ⁴Clinique Saint Jean de Dieu, Dept. of Urology, Paris, France, ⁵Rangueil University Hospital, Dept. of Urology, Toulouse, France, ⁶Grenoble University Hospital, Dept. of Urology, Grenoble, France, ⁷Hospices Civils de Lyon, Edouard Herriot Hospital, University Lyon 1, Dept. of Urinary and Vascular Radiology, Lyon, France, ⁸Pitié Salpêtrière University Hospital, Pierre et Marie Curie University, Dept. of Urology, Paris, France, ⁹Institut Universitaire du Cancer de Toulouse – Oncopole, Dept. of Urology, Toulouse, France

16:56 - 17:03

Summary and context

G. Van Leenders, Rotterdam (NL)